<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301752</url>
  </required_header>
  <id_info>
    <org_study_id>Mansoura University 13</org_study_id>
    <nct_id>NCT04301752</nct_id>
  </id_info>
  <brief_title>Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis</brief_title>
  <official_title>Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brucellosis is a common zoonotic infection in many parts of the world including the
      Mediterranean and Middle Eastern countries.

      Neurobrucellosis may develop at any stage of disease and may have widely variable
      manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis,
      peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brucellosis is a common zoonotic infection in many parts of the world including the
      Mediterranean and Middle Eastern countries.

      Neurobrucellosis may develop at any stage of disease and may have widely variable
      manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis,
      peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

      The aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have
      detailed general and neurologic features
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MoCA s</measure>
    <time_frame>24 hours</time_frame>
    <description>Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were &lt;26 .</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Brucellosis</condition>
  <arm_group>
    <arm_group_label>Neurobrucellosis</arm_group_label>
    <description>Brucellosis associated with neuropsychiatric manifestations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-neurobrucellosis</arm_group_label>
    <description>Brucellosis not associated with neuropsychiatric manifestations</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MoCA</intervention_name>
    <description>Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were &lt;26. Maximum score is 30.</description>
    <arm_group_label>Neurobrucellosis</arm_group_label>
    <arm_group_label>Non-neurobrucellosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        82 consecutive patients with brucellosis (18 patients with neuropsychiatric manifestations
        and 64 patients without neuropsychiatric manifestations) were recruited.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age with laboratory-confirmed brucellosis

        Exclusion Criteria:

          -  Previous neuropsychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esmael M Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Prof of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2921-5.</citation>
  </results_reference>
  <results_reference>
    <citation>Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005 Jun 2;352(22):2325-36. Review.</citation>
    <PMID>15930423</PMID>
  </results_reference>
  <results_reference>
    <citation>Finn TB. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases. 2nd ed. New York: Elsevier, 2004:1665-9.</citation>
  </results_reference>
  <results_reference>
    <citation>Eren S, Bayam G, Ergönül O, Celikbaş A, Pazvantoğlu O, Baykam N, Dokuzoğuz B, Dilbaz N. Cognitive and emotional changes in neurobrucellosis. J Infect. 2006 Sep;53(3):184-9. Epub 2006 May 2.</citation>
    <PMID>16647757</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Esmael</investigator_full_name>
    <investigator_title>Assistant Prof of Neurology</investigator_title>
  </responsible_party>
  <keyword>Brucellosis, neuropsychiatric manifestations, cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brucellosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

